Arcturus Therapeutics to Present at the 13th Annual Needham Healthcare Conference
SAN DIEGO, April 7, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a preclinical-stage RNA medicines company pursuing rare diseases, today announced its President & CEO, Joseph E. Payne, has been invited to present at the 13th Annual Needham Healthcare Conference 2014, being held April 8-9 at The Westin Grand Central Hotel in New York City. In addition to a corporate summary, Payne's presentation will provide new data on the targeted delivery of RNA to the liver and kidney, broad biodistribution including tumor uptake, reduction of off-target effects and improved potency, and breakthrough mutant allele-selective silencing utilizing Arcturus' core technologies LUNARTM delivery and UNA chemistry. The company presentation will be on Tuesday, April 8, 1:10 PM.
"Arcturus is honored to be one of the few private companies selected to present at the 13th Annual Needham Healthcare Conference which connects leading emerging life science companies and investors across the globe," said Joseph E. Payne, Arcturus' President & CEO. "The Needham Healthcare Conference provides Arcturus another opportunity to showcase our exceptional LUNARTM delivery and UNA chemistry platform technologies – and how they are being harnessed to build an outstanding RNA therapeutics pipeline led by our flagship asset targeting TTR-mediated Amyloidosis."
About Transthyretin (TTR)-Mediated Amyloidosis
Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, which is mainly synthesized in the liver, causes errant amyloid proteins to aggregate and deposit, destroying body organs and tissue, such as the peripheral nerves and heart. TTR-mediated polyneuropathy (FAP) affects approximately 10,000 people and TTR-mediated cardiomyopathy (FAC) affects at least 40,000 people with the mean survival of ~2.5 years. With limited therapeutic options, there is a substantial unmet need for effective medicines for patients suffering from TTR-mediated diseases.
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNARTM, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, and microRNA oligotherapeutics. The company owns Unlocked Nucleic Acid (UNA) chemistry technology and patent portfolio (32 patents, USPTO granted) enabling the targeting of any gene in the human genome. For more information, visit www.ArcturusRx.com.
SOURCE Arcturus Therapeutics